← Back to Clinical Trials
Recruiting NCT06932835

NCT06932835 Comparison of Postoperative Analgesic Efficacy of Transversus Abdominis Plane Block (TAP) and Modified Thoracoabdominal Nerve Block (M-TAPA)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06932835
Status Recruiting
Phase
Sponsor Ankara Etlik City Hospital
Condition Laparoskopic Cholecystectomy
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2025-06-02
Primary Completion 2026-04-11

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Transversus Abdominis Plane (TAP) BlockModified Thoracoabdominal Nerve Block (M-TAPA)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 80 participants in total. It began in 2025-06-02 with a primary completion date of 2026-04-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Laparoscopic cholecystectomy is a frequently performed surgical procedure and is considered the gold standard for treating symptomatic gallstone disease. Although laparoscopic cholecystectomy is considered minimally invasive, it can cause moderate to severe pain in the postoperative period. Poorly controlled early postoperative pain can impair recovery quality and increase the risk of postoperative pulmonary complications as a risk factor for chronic pain development. Multimodal analgesia, including opioids, is used to limit pain following laparoscopic cholecystectomy. However, opioid treatment may lead to side effects such as postoperative nausea and vomiting (PONV), respiratory depression, and constipation. Nerve blocks provide better pain control, reduce opioid consumption in the postoperative period, and offer advantages such as fewer side effects and a lower risk of pulmonary and cardiac complications. In our clinic, a multimodal analgesia approach is preferred for patients undergoing laparoscopic cholecystectomy. In addition to intravenous analgesic agents, peripheral nerve blocks are administered based on patient preference (for all eligible and consenting patients). This study aims to compare the postoperative analgesic efficacy of the Transversus Abdominis Plane (TAP) Block and the Modified Thoracoabdominal Nerve Block with a Pericostal Approach (M-TAPA) in patients undergoing laparoscopic cholecystectomy. Standard analgesic methods are applied to patients who do not consent to peripheral nerve block administration.

Eligibility Criteria

Inclusion Criteria: * 18 to 65 years old * American Society of Anesthesiologists (ASA) physical status I-II-III * Body mass index 18 to 30 kg/m2 * Elective laparoscopic cholecystectomy surgery Exclusion Criteria: * Under 18 and over 65 * ASA score IV and above * Advanced co-morbidity * History of bleeding diathesis * Patient refusing the procedure * Chronic opioid or analgesic use * Patients who will operate under emergency conditions * Block injection site infection * Known allergy to local anesthetics * Pregnancy

Contact & Investigator

Central Contact

MÜRÜVVET TAŞKIR TURAN, MD

✉ taskirmuruvvet@gmail.com

📞 00905065536934

Frequently Asked Questions

Who can join the NCT06932835 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Laparoskopic Cholecystectomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06932835 currently recruiting?

Yes, NCT06932835 is actively recruiting participants. Contact the research team at taskirmuruvvet@gmail.com for enrollment information.

Where is the NCT06932835 trial being conducted?

This trial is being conducted at Yenimahalle, Turkey (Türkiye).

Who is sponsoring the NCT06932835 clinical trial?

NCT06932835 is sponsored by Ankara Etlik City Hospital. The trial plans to enroll 80 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology